2024年10月29日 · VALANX' novel protein conjugation platform. Through the power of synthetic biology and genetic code expansion we have developed a novel site-specific protein conjugation platform that allows precise control over conjugation site and number of conjugations on the protein of interest.

VALANX Biotech. was founded in 2017 as a spin-off of the Graz University of Technology. Our Mission. is to make the struggle of precise, reproducible protein conjugation a thing of the past, for the benefit of our partners, customers and patients. Our Vision

https://www.valanx.bio/wp-content/uploads/2024/10/animation-with-music.mp4 Genetic code expansion and synthetic amino acid incorporation Our technology completely frees up one codon of the genetic code to be used by our proprietary synthetic amino acid with no loss in expression system viability or yield.

Our CEO, Michael Lukesch, is there to talk about our 3rd generation antibody-drug-conjugate technology and how VALANX will usher in a new generation of optimized ADCs.

2023年11月9日 · VALANX Biotech was founded in 2017 as a spin-off of the Graz University of Technology with IP borne out of the doctoral studies of its founder, Michael Lukesch. Our Mission is to make the struggle of precise, reproducible protein conjugation a thing of the past, for the benefit of our partners, customers and patients.

2020年5月13日 · Valanx Biotech is a university spin-out offering a patented method for high-efficiency protein conjugation for cancer drug targeting and other uses. Through the power of synthetic biology and genetic-code expansion, we have developed a novel site-specific protein conjugation platform that allows precise control over a conjugation site and the ...

VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development.

The possibilities VALANX offers up to now. Antibody-drug conjugates ADC. ADC is the abbreviation for Antibody-drug conjugates which is a novel method to specifically transport drugs to and attack malignant cells like cancer cells. This dual therapy constitutes of a monoclonal anti body and a toxic drug which degrades or attacks the cancer cells.

2024年10月29日 · Using synthetic biology, FinaBio and VALANX have created ClickCRM, a product that will enable the precise conjugation of antigens to the widely used carrier protein, CRM 197. ClickCRM has defined...

VALANX Biotech GmbH Profile Through the power of synthetic biology and genetic code expansion we have developed a novel site-specific protein conjugation platform that allows precise control over conjugation site and number of conjugations on the protein of interest.